Importantly, for the U.K., Oxbryta was granted EAMS designation, which provides two key advantages: first, patients that meet the eligibility criteria can gain early pre-license access to Oxbryta; second, medicines under EAMS that receive marketing authorization by the MHRA, as well as a positive assessment by NICE benefit from accelerated NHS England commissioning. While we work through the process in the EU and U.K., we are working to build momentum with early access programs with patients enrolled in France, the U.K. and Germany, markets where the majority of sickle cell patients live.